Pradžia › Plaučių ligos › New Jersey
Plaučių ligos klinikiniai tyrimai New Jersey
6 tyrimai dėl Plaučių ligos ieško dalyvių vietose New Jersey.
Miestai New Jersey
Oficialus tyrimo tekstas (anglų kalba)
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- Holy Name Medical Center, Teaneck
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07013474A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Rutgers, Robert Wood Johnson Medical School, New Brunswick
- Circuit Clinical / Impact Medical Allergy, Asthma & Immunology, Riverdale
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-22 · NCT06977581A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- The Valley Hospital, Inc., Paramus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06119581A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Cancer Center - Monmouth, Middletown
- Memorial Sloan Kettering Cancer Center - Bergen, Montvale
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT05967689Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- MD Anderson Cooper, Camden
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-06-26 · NCT04614103TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
- Rutgers Cancer Institute, New Brunswick
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 50 iki 77 · Visoms lytims · Atnaujinta 2025-12-02 · NCT07165691Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.